BS
EDIT icon

Boenning & Scattergood’s Editas Medicine EDIT Stock Holding History

Boenning & Scattergood’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,900
Closed -$278K – 384
2021
Q2 		$278K Buy
+4,900
New +$181K 0.05% 315

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boenning & Scattergood's EDIT Position: Q3 2021 in Review

Boenning & Scattergood sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 4,900 shares — an estimated $278K sold.

Boenning & Scattergood first reported a position in EDIT in Q2 2021 and held it in 1 quarter. The position peaked at $278K in Q2 2021. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

  • Boenning & Scattergood reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
  • Boenning & Scattergood sold 4,900 Editas Medicine shares in Q3 2021, an estimated $278K.
  • Boenning & Scattergood first reported a position in Editas Medicine in Q2 2021 and held it in 1 quarter.
  • Boenning & Scattergood's Editas Medicine position peaked at $278K in Q2 2021.
  • 318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on Boenning & Scattergood's 13F filing for Q3 2021, filed 21 Oct 2021.